Ireland
--:--IST
Recruiting Not applicable

Intracerebral Electrical Stimulation and the Optimisation of Presurgical Planning in Drug-refractory Partial Epilepsy

NCT03738072 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2018-11-14
Last updated
2026-05-07

Condition(s) studied

Epilepsy

Investigational drug(s) / intervention(s)

StiMiC stimulation condition

StiMiC stimulation condition: This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition

Study summary

Patients with drug-refractory epilepsy sometimes need to be implanted with intracerebral electrodes in order to identify their seizure onset zone. During this procedure, direct electrical brain stimulations represent a standard clinical practice to assess seizure sensitivity and for functional mapping. This study aims at assessing if extending the range of stimulation frequencies of the usual clinical frequencies is of benefit for the definition of the seizure onset zone and hence for the presurgical planning.

Eligibility

Sex
ALL
Min age
12 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * all patients undergoing a stereo-electro-encephalography (SEEG), age 12 to 65 years old. Exclusion Criteria: * usual excluding criteria for a SEEG.

Primary outcome measure(s)

  • Comparison of the index of efficient stimulation between standard clinical stimulation condition and StiMic stimulation condition — 22 days after implantation of electrode
    Comparison for each patient of the index of efficient stimulations (assessed as any stimulation having yielded an electrical or clinical effect over the total number of stimulations) for each condition (standard clinical stimulations condition vs research stimulations condition).

Trial sites (1)

FacilityCityRegionStatus
CHU de Toulouse Toulouse France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03738072 on ClinicalTrials.gov ↗ ← All trials in France